Outlook Therapeutics (OTLK) announced that Russell Trenary has stepped down as the company’s president and CEO, effective immediately. Lawrence Kenyon, executive VP, CFO and member of the board of directors, has been appointed interim CEO. Kenyon has served as the company’s CFO and secretary since September 2015. He has been a member of Outlook Therapeutics’ board of directors since August 2018 and also served as the company’s president and CEO from August 2018 to July 2021. The company has engaged an executive search firm to work with the board of directors to identify a permanent CEO.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK: